ClinicalTrials.gg
CompletedNCT01651156Updated Dec 30, 2013

Efficacy and Safety Study of Tolvaptan to Treat Patients With Cardiac Edema

A Phase 3 interventional study of Tolvaptan and Placebo in Cardiac Edema, sponsored by Otsuka Beijing Research Institute. Completed at 1 site in China. Open to participants aged 20 Years to 85 Years. Per ClinicalTrials.gov, last updated 2013-12-30.

Sponsored by Otsuka Beijing Research Institute (part of Otsuka Holdings Co., Ltd.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
244
Allocation
Randomized
Ages
20 Years to 85 Years
Sex
All
01

Study summary

A randomized, double-blind, multicenter, placebo-controlled, parallel study to evaluate the efficacy and safety of Tolvaptan in the treatment of patients with cardiac edema (body fluid retention caused by congestive heart failure) based on the conventional therapy.

To evaluate the efficacy and safety of Tolvaptan 15 mg on congestive heart failure patients with body fluid retention after current diuretic treatment, after continuous treatment of 7 days' oral Tolvaptan 15mg or placebo.

Read the detailed description
  • A randomized, double-blind, multicenter, placebo-controlled, parallel study
  • Study population: The congestive heart failure patients with body fluid retention after received current diuretics therapy
  • Number of patients: Patients will be randomly assigned to Tolvaptan and placebo group in 1:1 ratio, 120 patients in each group, 240 patients in total
  • Group assignment method: Tolvaptan 15 mg group: conventional therapy + Tolvaptan 15 mg Placebo group: conventional therapy + placebo
  • Administration and dosage of the study drug: Once daily, 1 tablet be taken orally after breakfast, for successive 7 days
  • Study period:
  • Screening period (4 days in minimum, 7 days in maximum), including:

Screening period: from the time the informed consent form is signed to Day -4 Observation period: 3 days before drug administration

  • Treatment period: 7 days
  • Follow up visits: Day 8 (efficacy evaluation day) and Day 7 (+3) after the last dosing
  • Post treatment survey: Day 14 (+3) after the last dosing
02

Conditions studied

  • Cardiac Edema
03

In context

Lead sponsor

Otsuka Beijing Research Institute is the lead sponsor of 36 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients treated with one of the oral diuretic therapy standards (include the patients who will be treated with one of the oral diuretic therapy standards from the beginning of the observation period):

    1. Only 40 mg/day furosemide taken orally or other oral loop diuretics equivalent to 40 mg/day furosemide note 1)
    2. Combination treatment of oral loop diuretics and thiazide diuretics (no dosage limitation)
    3. Combination treatment of oral loop diuretics and aldosterone antagonists (no dosage limitation)
  • Because of the existence of excess body fluid retention, the congestive heart failure patient has at least one of these symptoms (the lower extremity edema, pulmonary congestion note 2), or jugular vein engorgement).
  • 20-85 years of age (inclusive) at the time of signing the document.
  • Gender: male or female.
  • Inpatients or patient who would be hospitalized from one day before the observation period to the end of efficacy evaluation examination after the last dosing (from Day -4 to the end of efficacy evaluation examination after the last dosing).
  • Patient who have signed the informed consent form.

Exclusion criteria

Exclusion Criteria:

  • Patients equipped with circulatory assistant device.
  • Patients with any of following diseases, complications or symptoms:

    1. Suspected decreased blood volume
    2. Obstructive hypertrophic cardiomyopathy
    3. Severe aortic stenosis
    4. Hepatic coma
  • Patients with history of acute myocardial infarction within 30 days prior to screening.
  • Patients with diagnosed active myocarditis or amyloid cardiomyopathy.
  • Patients with the following diseases, complications or symptoms:

    1. Poorly controlled diabetes with a fasting glucose more than 220 mg/dL (or 12.21 mmol/L)
    2. Anuria
    3. Dysuria caused by urethral stricture, calculus or tumor
  • Patients with the following medical history of:

    1. Sustained ventricular tachycardia or ventricular fibrillation within 30 days prior to screening
    2. History of cerebrovascular accident within the past 30 days
    3. Past allergy or hypersensitive reactions to benzodiazepines (e.g. mozavaptan hydrochloride or benazepril hydrochloride)
  • Obese patients whose (BMI = body weight (kg) / height (m)2 ) is more than 35.
  • Patients with systolic pressure below 90 mmHg in supine position.
  • Patients with any of the following abnormal laboratory test parameters:

    1. Total > 2.5 times the value
    2. Serum creatine > 2.5 times the upper limits of normal value
    3. Serum Na+ > 145 mmol/L (or higher than the upper limits of normal value)
    4. Serum K+ > 5.5 mmol/L
  • Patients who unable to take medicine orally.
  • Female patients who are pregnant, breast-feeding, at childbearing ages, or with pregnancy plan.
  • Patients who participated in clinical trials of other medicine and took other study drugs within 30 days prior to sign the form.
  • Patients who participated in the clinical trial of Tolvaptan and took Tolvaptan previously.
  • Patients who have received approved Tolvaptan tablets (Trade name: Samsca) previously.
  • Except for the above, patients who were unsuitable to participate in this trial in the investigator's opinion.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
244 participants (actual)

Study arms

  • Placebo comparator
    placebo

    Frequency: once per day Duration: 7days

    Drug: Placebo

  • Experimental
    Tolvaptan

    Tolvaptan tablet Frequency: once per day Duration: 7days

    Drug: Tolvaptan

Interventions

  • oral taken

    Also known as: Samsca

  • DrugPlacebo
06

What researchers measure

Primary outcomes

  1. body weight (change from baseline)

    Time frame: screening day, Day-3, Day-2, Day-1, Day1, Day2, Day3, Day4, Day5, Day6, Day7, Day8, Day(7+3)

Secondary outcomes

  1. Body weight (percent change from baseline)

    Time frame: screening day, Day-3, Day-2, Day-1, Day1, Day2, Day3, Day4, Day5, Day6, Day7, Day8, Day(7+3)

07

Study locations

1 site
  • Zhejiang Hospital
    Hangzhou, Zhejiang 310013, China
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2012, a primary completion of Jul 2013 and a completion of Jul 2013. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 24, 2012
First posted
Jul 26, 2012
Start
Jul 2012
Primary completionActual
Jul 2013
CompletionActual
Jul 2013
Last update
Dec 30, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 30, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01651156
Responsible party
Sponsor
First posted
Jul 26, 2012
Start date
Jul 2012
Primary completion
Jul 2013
Completion
Jul 2013
Last update
Dec 30, 2013

Study contacts

Zhang Jian
principal investigator · Fuwai Cardiovascular hospital

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tolvaptan

Start the discussion